Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Cytostatic Therapy | Research

Associations of financial toxicity with symptoms and unplanned healthcare utilization among cancer patients taking oral chemotherapy at home: a prospective observational study

Authors: Yongfeng Chen, Zhenxiang Chen, Haiyun Jin, Yanrong Chen, Jinbing Bai, Guifen Fu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Cancer patients with financial toxicity experience psychological distress and often miss medical appointments and quit treatments early, which could be a barrier to the effective management of oral chemotherapy drugs at home. This study explores whether financial toxicity predicts symptoms and unplanned healthcare utilization among cancer patients taking oral chemotherapy at home, which will contribute to the safe management of oral chemotherapy.

Methods

Data in this study was from a prospective observational study, which was conducted between October 2018 and December 2019. 151 patients completed the Comprehensive Score for Financial Toxicity at discharge and completed the MD Anderson Symptom Inventory and unplanned healthcare utilization questionnaires after finishing one cycle of oral chemotherapy at home. Regression analyses were conducted to explore the associations of financial toxicity with symptoms and unplanned healthcare utilization.

Results

Among 151participants, 88.08% reported severe or moderate financial toxicity, 43.05% reported symptom interference, and 31.79% reported unplanned healthcare utilization while taking oral chemotherapy at home. Patients between the age of 45-60y (p = 0.042) have higher financial toxicity, while those living in urban areas (p = 0.016) have lower financial toxicity. Patients with worse financial toxicity suffered increased symptoms of fatigue, emotional distress, disturbed sleep, and lack of appetite. Consequently, their mood and personal relation with other significant suffered. However, no statistical differences in unplanned healthcare utilization were found among patients with different levels of financial toxicity.

Conclusion

Middle-aged adults and those living in suburban or rural areas experienced worse financial toxicity than other groups. Patients with worse financial toxicity experienced more severe psychological symptoms (e.g., fatigue, distress, disturbed sleep, and lack of appetite) and affective interference (e.g., mood and relations with others). Identifying at-risk patients is necessary to offer tailored support for psychological symptom management.
Literature
1.
go back to reference Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer Incidence, Mortality, Years of Life Lost, Years lived with disability, and disability-adjusted life years for 29 Cancer Groups from 2010 to 2019: a systematic analysis for the global burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–44.CrossRefPubMed Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer Incidence, Mortality, Years of Life Lost, Years lived with disability, and disability-adjusted life years for 29 Cancer Groups from 2010 to 2019: a systematic analysis for the global burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–44.CrossRefPubMed
2.
go back to reference Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9.CrossRef Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9.CrossRef
3.
go back to reference Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):1–14.CrossRef Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):1–14.CrossRef
4.
go back to reference Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, et al. Value, Access, and cost of Cancer Care Delivery at Academic Cancer Centers. J Natl Compr Canc Netw. 2016;14(7):837–47.CrossRefPubMed Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, et al. Value, Access, and cost of Cancer Care Delivery at Academic Cancer Centers. J Natl Compr Canc Netw. 2016;14(7):837–47.CrossRefPubMed
5.
go back to reference Cass Y, Connor TH, Tabachnik A. Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting. J Oncol Pharm Pract. 2017;23(5):350–78.CrossRefPubMed Cass Y, Connor TH, Tabachnik A. Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting. J Oncol Pharm Pract. 2017;23(5):350–78.CrossRefPubMed
6.
go back to reference Abrams HR, Durbin S, Huang CX, Johnson SF, Nayak RK, Zahner GJ, et al. Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med. 2021;11(11):2043–54.CrossRefPubMed Abrams HR, Durbin S, Huang CX, Johnson SF, Nayak RK, Zahner GJ, et al. Financial toxicity in cancer care: origins, impact, and solutions. Transl Behav Med. 2021;11(11):2043–54.CrossRefPubMed
7.
go back to reference Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–65.CrossRefPubMedPubMedCentral Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–65.CrossRefPubMedPubMedCentral
8.
go back to reference Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial Hardships Experienced by Cancer Survivors: A Systematic Review.J Natl Cancer Inst. 2017;109(2). Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial Hardships Experienced by Cancer Survivors: A Systematic Review.J Natl Cancer Inst. 2017;109(2).
10.
go back to reference Fu W, Zhao S, Zhang Y, Chai P, Goss J. Research in health policy making in China: out-of-pocket payments in Healthy China 2030. BMJ (Clinical research ed).360:k234-k. Fu W, Zhao S, Zhang Y, Chai P, Goss J. Research in health policy making in China: out-of-pocket payments in Healthy China 2030. BMJ (Clinical research ed).360:k234-k.
11.
go back to reference Jia-hui W, Hang Y, Xin Z, Qunhong W, Linghan S, Ye L, et al. Out-of-pocket and reimbursed expenses of inpatients with major noncommunicable chronic diseases in China, 2013. Chin J Public Health. 2021;37(4):623–6. Jia-hui W, Hang Y, Xin Z, Qunhong W, Linghan S, Ye L, et al. Out-of-pocket and reimbursed expenses of inpatients with major noncommunicable chronic diseases in China, 2013. Chin J Public Health. 2021;37(4):623–6.
12.
go back to reference Wang H, Ma L, Gu X-F, Li L, Wang W-J, Du L-B et al. Out-of-pocket medical expenditure and associated factors of advanced colorectal cancer in China: a multi-center cross-sectional study.Annals of Translational Medicine. 2022;10(6). Wang H, Ma L, Gu X-F, Li L, Wang W-J, Du L-B et al. Out-of-pocket medical expenditure and associated factors of advanced colorectal cancer in China: a multi-center cross-sectional study.Annals of Translational Medicine. 2022;10(6).
13.
go back to reference Huang HY, Shi JF, Guo LW, Bai YN, Liao XZ, Liu GX, et al. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. Chin J Cancer. 2017;36(1):41.CrossRefPubMedPubMedCentral Huang HY, Shi JF, Guo LW, Bai YN, Liao XZ, Liu GX, et al. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. Chin J Cancer. 2017;36(1):41.CrossRefPubMedPubMedCentral
14.
go back to reference Xu B, Hu L, Cheng Q, So WK. A systematic review of financial toxicity among cancer patients in China.Asia-Pacific journal of oncology nursing. 2022. Xu B, Hu L, Cheng Q, So WK. A systematic review of financial toxicity among cancer patients in China.Asia-Pacific journal of oncology nursing. 2022.
15.
go back to reference Longo C, Fitch M, Banfield L, Hanly P, Yabroff K, Sharp L. Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2020;28(10):4645–65.CrossRefPubMed Longo C, Fitch M, Banfield L, Hanly P, Yabroff K, Sharp L. Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2020;28(10):4645–65.CrossRefPubMed
16.
go back to reference Lentz R, Benson AB 3rd, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol. 2019;120(1):85–92.CrossRefPubMed Lentz R, Benson AB 3rd, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol. 2019;120(1):85–92.CrossRefPubMed
17.
go back to reference Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17(1):28–40.CrossRefPubMed Imber BS, Varghese M, Ehdaie B, Gorovets D. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17(1):28–40.CrossRefPubMed
18.
go back to reference Sadigh G, Lava N, Switchenko J, Duszak R Jr, Krupinski EA, Meltzer C, et al. Patient-reported financial toxicity in multiple sclerosis: predictors and association with care non-adherence. Mult Scler. 2021;27(3):453–64.CrossRefPubMed Sadigh G, Lava N, Switchenko J, Duszak R Jr, Krupinski EA, Meltzer C, et al. Patient-reported financial toxicity in multiple sclerosis: predictors and association with care non-adherence. Mult Scler. 2021;27(3):453–64.CrossRefPubMed
19.
go back to reference Chan RJ, Gordon LG, Tan CJ, Chan A, Bradford NK, Yates P, et al. Relationships between Financial Toxicity and Symptom Burden in Cancer Survivors: a systematic review. J Pain Symptom Manage. 2019;57(3):646–60. e1.CrossRefPubMed Chan RJ, Gordon LG, Tan CJ, Chan A, Bradford NK, Yates P, et al. Relationships between Financial Toxicity and Symptom Burden in Cancer Survivors: a systematic review. J Pain Symptom Manage. 2019;57(3):646–60. e1.CrossRefPubMed
20.
go back to reference Printz C. Drug parity legislation: states, organizations seek to make oral cancer drugs more affordable. Cancer. 2014;120(3):313–4.CrossRefPubMed Printz C. Drug parity legislation: states, organizations seek to make oral cancer drugs more affordable. Cancer. 2014;120(3):313–4.CrossRefPubMed
21.
go back to reference Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. Lancet Oncol. 2021;22(12):e541–e9.CrossRefPubMed Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. Lancet Oncol. 2021;22(12):e541–e9.CrossRefPubMed
22.
go back to reference Vuelta-Arce M, Chiapella-Mico C, Mestre-Prad MT, Teixido-Huerta X, Del Estal-Jimenez J, Rodriguez-Gias E, et al. Comprehensive tackling to the safe handling of hazardous drugs: a multidisciplinary approach to clinical practice. Int J Occup Med Environ Health. 2020;33(5):621–34.CrossRefPubMed Vuelta-Arce M, Chiapella-Mico C, Mestre-Prad MT, Teixido-Huerta X, Del Estal-Jimenez J, Rodriguez-Gias E, et al. Comprehensive tackling to the safe handling of hazardous drugs: a multidisciplinary approach to clinical practice. Int J Occup Med Environ Health. 2020;33(5):621–34.CrossRefPubMed
23.
go back to reference Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011;7(1):7–12.CrossRefPubMedPubMedCentral Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011;7(1):7–12.CrossRefPubMedPubMedCentral
24.
go back to reference Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620–9.CrossRefPubMedPubMedCentral Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620–9.CrossRefPubMedPubMedCentral
25.
go back to reference Solomon JM, Ajewole VB, Schneider AM, Sharma M, Bernicker EH. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract. 2019;25(7):1564–9.CrossRefPubMed Solomon JM, Ajewole VB, Schneider AM, Sharma M, Bernicker EH. Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. J Oncol Pharm Pract. 2019;25(7):1564–9.CrossRefPubMed
26.
go back to reference Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ, et al. Patient experiences with oral chemotherapy: adherence, symptoms, and Quality of Life. J Natl Compr Canc Netw. 2019;17(3):221–8.CrossRefPubMedPubMedCentral Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ, et al. Patient experiences with oral chemotherapy: adherence, symptoms, and Quality of Life. J Natl Compr Canc Netw. 2019;17(3):221–8.CrossRefPubMedPubMedCentral
27.
go back to reference Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. J Natl Compr Canc Netw. 2012;10(5):618–25.CrossRefPubMed Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. J Natl Compr Canc Netw. 2012;10(5):618–25.CrossRefPubMed
28.
go back to reference Chen Y, Zhang L, Wei C, Chen F, Bai J. Predictors of oral chemotherapy adherence at home among Chinese cancer patients: An observational prospective study.J Clin Nurs. 2021. Chen Y, Zhang L, Wei C, Chen F, Bai J. Predictors of oral chemotherapy adherence at home among Chinese cancer patients: An observational prospective study.J Clin Nurs. 2021.
29.
go back to reference de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial toxicity (COST). Cancer. 2017;123(3):476–84.CrossRefPubMed de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial toxicity (COST). Cancer. 2017;123(3):476–84.CrossRefPubMed
30.
go back to reference Esselen KM, Gompers A, Hacker MR, Bouberhan S, Shea M, Summerlin SS, et al. Evaluating meaningful levels of financial toxicity in gynecologic cancers. Int J Gynecol Cancer. 2021;31(6):801–6.CrossRefPubMedPubMedCentral Esselen KM, Gompers A, Hacker MR, Bouberhan S, Shea M, Summerlin SS, et al. Evaluating meaningful levels of financial toxicity in gynecologic cancers. Int J Gynecol Cancer. 2021;31(6):801–6.CrossRefPubMedPubMedCentral
31.
go back to reference Souza J, Wroblewski K, Proussaloglou E, Nicholson L, Wang Y. Validation of a financial toxicity (FT) grading system. J Clin Oncol. 2017;35(15suppl):6615.CrossRef Souza J, Wroblewski K, Proussaloglou E, Nicholson L, Wang Y. Validation of a financial toxicity (FT) grading system. J Clin Oncol. 2017;35(15suppl):6615.CrossRef
32.
go back to reference Yu HH, Bi X, Liu YY. [Reliability and validity of the chinese version on Comprehensive Scores for Financial Toxicity based on the patient-reported outcome measures]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(8):1118–20.PubMed Yu HH, Bi X, Liu YY. [Reliability and validity of the chinese version on Comprehensive Scores for Financial Toxicity based on the patient-reported outcome measures]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(8):1118–20.PubMed
33.
go back to reference Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.CrossRefPubMed Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.CrossRefPubMed
34.
go back to reference Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer. 2004;101(8):1890–901.CrossRefPubMed Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer. 2004;101(8):1890–901.CrossRefPubMed
35.
go back to reference Chen R-w, Yang S-l, Xu Z-y, Peng M, Chen M-n, Wang Q-s, et al. Validation and application of the Chinese Version of the MD Anderson symptom inventory gastrointestinal cancer module (MDASI-GI-C). J Pain Symptom Manag. 2019;57(4):820–7.CrossRef Chen R-w, Yang S-l, Xu Z-y, Peng M, Chen M-n, Wang Q-s, et al. Validation and application of the Chinese Version of the MD Anderson symptom inventory gastrointestinal cancer module (MDASI-GI-C). J Pain Symptom Manag. 2019;57(4):820–7.CrossRef
36.
go back to reference Weiss ME, Lokken L. Predictors and outcomes of postpartum mothers’ perceptions of readiness for discharge after birth. J Obstet Gynecol Neonatal Nurs. 2009;38(4):406–17.CrossRefPubMed Weiss ME, Lokken L. Predictors and outcomes of postpartum mothers’ perceptions of readiness for discharge after birth. J Obstet Gynecol Neonatal Nurs. 2009;38(4):406–17.CrossRefPubMed
37.
go back to reference Mejri N, Berrazega Y, Boujnah R, Rachdi H, El Benna H, Labidi S, et al. Assessing the financial toxicity in tunisian cancer patients using the Comprehensive score for Financial Toxicity (COST). Support Care Cancer. 2021;29(7):4105–11.CrossRefPubMed Mejri N, Berrazega Y, Boujnah R, Rachdi H, El Benna H, Labidi S, et al. Assessing the financial toxicity in tunisian cancer patients using the Comprehensive score for Financial Toxicity (COST). Support Care Cancer. 2021;29(7):4105–11.CrossRefPubMed
38.
go back to reference Rotter J, Spencer JC, Wheeler SB. Financial Toxicity in Advanced and Metastatic Cancer: overburdened and underprepared. J Oncol Pract. 2019;15(4):e300–e7.CrossRefPubMedPubMedCentral Rotter J, Spencer JC, Wheeler SB. Financial Toxicity in Advanced and Metastatic Cancer: overburdened and underprepared. J Oncol Pract. 2019;15(4):e300–e7.CrossRefPubMedPubMedCentral
39.
go back to reference Mack JW, Cronin A, Fasciano K, Block SD, Keating NL. Cancer treatment decision-making among young adults with lung and colorectal cancer: a comparison with adults in middle age. Psycho-oncology. 2016;25(9):1085–91.CrossRefPubMed Mack JW, Cronin A, Fasciano K, Block SD, Keating NL. Cancer treatment decision-making among young adults with lung and colorectal cancer: a comparison with adults in middle age. Psycho-oncology. 2016;25(9):1085–91.CrossRefPubMed
40.
go back to reference Meeker CR, Wong Y-N, Egleston BL, Hall MJ, Plimack ER, Martin LP, et al. Distress and financial distress in adults with Cancer: an age-based analysis. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2017;15(10):1224–33.CrossRefPubMed Meeker CR, Wong Y-N, Egleston BL, Hall MJ, Plimack ER, Martin LP, et al. Distress and financial distress in adults with Cancer: an age-based analysis. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2017;15(10):1224–33.CrossRefPubMed
41.
go back to reference Mols F, Tomalin B, Pearce A, Kaambwa B, Koczwara B. Financial toxicity and employment status in cancer survivors. A systematic literature review. Support Care Cancer. 2020;28(12):5693–708.CrossRefPubMedPubMedCentral Mols F, Tomalin B, Pearce A, Kaambwa B, Koczwara B. Financial toxicity and employment status in cancer survivors. A systematic literature review. Support Care Cancer. 2020;28(12):5693–708.CrossRefPubMedPubMedCentral
42.
go back to reference Kawasumi K, Kujirai A, Matsui R, Kawano Y, Yamaguchi M, Aoyama T. Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: a retrospective study. Mol Clin Oncol. 2021;14(1):12.CrossRefPubMed Kawasumi K, Kujirai A, Matsui R, Kawano Y, Yamaguchi M, Aoyama T. Survey of serious adverse events and safety evaluation of oral anticancer drug treatment in Japan: a retrospective study. Mol Clin Oncol. 2021;14(1):12.CrossRefPubMed
43.
go back to reference Jing J, Feng R, Zhang X, Li M, Gao J. Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China. Breast Cancer Res Treat. 2020;181(2):435–43.CrossRefPubMed Jing J, Feng R, Zhang X, Li M, Gao J. Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China. Breast Cancer Res Treat. 2020;181(2):435–43.CrossRefPubMed
44.
go back to reference Beeler WH, Bellile EL, Casper KA, Jaworski E, Burger NJ, Malloy KM, et al. Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncol. 2020;101:104521.CrossRefPubMed Beeler WH, Bellile EL, Casper KA, Jaworski E, Burger NJ, Malloy KM, et al. Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncol. 2020;101:104521.CrossRefPubMed
Metadata
Title
Associations of financial toxicity with symptoms and unplanned healthcare utilization among cancer patients taking oral chemotherapy at home: a prospective observational study
Authors
Yongfeng Chen
Zhenxiang Chen
Haiyun Jin
Yanrong Chen
Jinbing Bai
Guifen Fu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10580-4

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine